| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8773668 | Kidney International Reports | 2018 | 10 Pages |
Abstract
Daprodustat increased hemoglobin concentrations within the target range in 29% of chronic rhEPO-hyporesponsive subjects. No new safety concerns were identified in this short exploratory study.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Borut Cizman, Andy P. Sykes, Gitanjali Paul, Steven Zeig, Alexander R. Cobitz,